AUG 18, 2026 · PHASE 1 TRIAL
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
ClinicalTrials.gov
Phase 1 dose-escalation and expansion trial of a novel targeted radiopharmaceutical in multiple somatostatin-receptor–positive cancers; no results reported in this registry record.
Reported
Planned enrollment120
Study phasePhase 1
Primary outcome: MTD and safetyDLTs through 12 weeks (dose escalation); al…